Thank you, GY! Immensely helpfulASIC want all details to be...

Thank you, GY! Immensely helpful
ASIC want all details to be described in 2000 characters. Your description is excellent and comprehensive, which can guide any BIT SH to lodge complaint through ASIC.

Lots of questions remain unanswered by the management.
Why did MM and PN and Hoy not sketch this scenario? Why are they not dutiful? Is it because law is under their feet? Why are they getting paid?
....

Why are the prospectus not rejected by the ASX? The only option for MM and PN and Hoy is to give money to the compnay from their own pocket and give the true picture to the SHs to get money. Why did they not exercise their options? If they showed confidence in the compnay, SHs would show confidence to some extent.

They could raise money proactively. They could highlight the fact that C14 has identifed 7 potential partners and reached out them, and they could ask for money to secure the deal within a deadline, and the deal would be blockbuster in the history of the company....

Animal model ..... are just considered to be bogus at this stage to buy time as far as their animal model for COVID 19...

Is Biotron intentionally made to be at 0.3c/s so that it can be sucked?

BTW, final results analyses are still going on with the CROs that were busy with COVID and complex data set from the trials.....

There response to the ASX is not statisfactory.


Extracts from Prospectus " Biotron recognises that the path forward from this point for its HIV-1 program lies in the hands of a
pharmaceutical company that has additional resources and the necessary regulatory skills to move it
to the next stage of development. To that end, the Company appointed a US based advisory group,
C14, in late 2024 to assist with its ongoing endeavours to position BIT225 within the international
HIV-1 treatment landscape and find a potential strategic alliance, partnership or an acquirer of the
Company’s assets.
In addition to multinational pharmaceutical companies with programs in the HIV-1 space, C14 has
identified and reached out to additional potential partners across a broad geographic and infectious
disease landscape [ any response?]. This process is ongoing and is not a fast process, and additional time will be
required to undertake the necessary negotiations [ it will take time if no response , rigt?] to potentially finalise a deal.
...
In recent months the Directors have been aggressive in reducing costs across all operations. Staff
numbers and hours have been reduced [Freezing the remunerations of MM, PN, HOY until a deal] , all non-essential expenditures and activities have ceased.
..."